Core Viewpoint - Rosen Law Firm is encouraging investors of DexCom, Inc. to secure legal counsel before the December 29, 2025 deadline for a securities class action lawsuit related to misleading statements made by the company during the class period from July 26, 2024, to September 17, 2025 [1][2]. Group 1: Class Action Details - Investors who purchased DexCom securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by December 29, 2025 [3]. - The lawsuit alleges that DexCom made false statements regarding the reliability and safety of its G6 and G7 continuous glucose monitoring systems, which were not authorized by the FDA [5]. Group 2: Allegations Against DexCom - The lawsuit claims that DexCom's design changes to the G6 and G7 systems rendered them less reliable, posing health risks to users [5]. - It is alleged that the company overstated the enhancements and reliability of the G7 device while downplaying the severity of the issues related to the devices [5]. - The allegations suggest that DexCom faced increased regulatory scrutiny and potential legal, reputational, and financial harm due to these misleading statements [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing clients [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DexCom, Inc. regarding a class action lawsuit alleging that the company made misleading statements about its glucose monitoring products, G6 and G7, which may have health risks for users [1][3]. Group 1: Allegations Against DexCom - The complaint claims that DexCom made unauthorized design changes to the G6 and G7 glucose monitoring products, which were not approved by the U.S. Food and Drug Administration [3]. - These design changes allegedly made the G6 and G7 less reliable than previous versions, posing a material health risk to users who depend on these devices for accurate glucose readings [3]. - The enhancements claimed for the G7, including its reliability, accuracy, and functionality, were reportedly overstated by the defendants [3]. - The severity of the issues and health risks associated with the altered G7 devices was allegedly downplayed by the defendants [3]. - As a result of these actions, DexCom faced increased risks of regulatory scrutiny and potential legal, reputational, and financial harm [3]. - The public statements made by the defendants were claimed to be materially false and misleading throughout the relevant period [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as July 26, 2024, to September 17, 2025 [3]. - Shareholders are encouraged to register for the class action by December 26, 2025, to be eligible for potential recovery [4]. - Once registered, shareholders will receive updates on the case through a portfolio monitoring software [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [5]. - The firm aims to ensure that companies engage in responsible business practices and seeks recovery for investors who have suffered losses due to misleading statements or omissions [5].

Core Viewpoint - The article discusses a securities fraud class action lawsuit against DexCom, Inc. related to misleading statements and undisclosed risks associated with its G6 and G7 glucose monitoring devices, which allegedly posed health risks to users [3]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of investors who purchased DexCom securities between July 26, 2024, and September 17, 2025, alleging that the company made unauthorized design changes to its G6 and G7 devices, compromising their reliability and safety [3]. - Allegations include that DexCom overstated the enhancements and reliability of the G7 devices while downplaying the severity of health risks associated with them [3]. Regulatory Issues - On March 7, 2025, DexCom received a warning letter from the FDA regarding manufacturing and quality management concerns, leading to a share price decline of approximately 9.15%, from $77.84 to $70.72 [4]. - The FDA's published warning on March 25, 2025, indicated that the G6 and G7 devices were "adulterated" due to unauthorized modifications, causing inaccuracies that increased health risks for users, resulting in a further share price drop of about 2.4% [5]. Market Reactions - On September 8, 2025, Oppenheimer downgraded DexCom's rating from "outperform" to "perform," citing rising concerns about the G7's accuracy and performance, which led to a share price decline of approximately 3.1% [6]. - A report by Hunterbrook Media LLC on September 18, 2025, highlighted severe health risks linked to the G7 devices, including hospitalizations and fatalities, causing a significant share price drop of about 11% [7].

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. for allegedly making false and misleading statements regarding its products during the specified class period [2][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased DexCom securities between July 26, 2024, and September 17, 2025 [2]. - Investors have until December 26, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that DexCom made unauthorized design changes to the G6 and G7 devices, which were not approved by the FDA [3]. - These design changes allegedly made the G6 and G7 devices less reliable, posing health risks to users who depend on them for accurate glucose readings [3]. - The lawsuit claims that DexCom overstated the enhancements and reliability of the G7 device, downplayed the severity of issues with the G7, and faced increased regulatory scrutiny and potential legal repercussions as a result [3]. Group 3: Next Steps for Investors - Investors who suffered losses or have information regarding the claims are encouraged to contact the law firm for more details [4].

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. and its senior executives for securities fraud following significant stock declines attributed to potential violations of federal securities laws [1][2]. Group 1: Lawsuit Details - Investors have until December 26, 2025, to request to lead the case, which is pending in the U.S. District Court for the Southern District of New York [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of DexCom investors [2]. Group 2: Product Issues - DexCom manufactures continuous glucose monitoring systems, including the G6 and G7, which were marketed as highly accurate [3]. - Allegations state that unauthorized design changes were made to the G6 and G7, compromising their accuracy and exposing users to health risks [4]. Group 3: Stock Performance - DexCom's stock experienced significant declines due to quality issues with the G6 and G7, including a drop of $7.12 per share (over 9%) following an FDA warning letter on March 7, 2025 [5]. - After the FDA published the warning letter on March 25, 2025, the stock fell an additional $3.19 per share (over 4%) [6]. - A report by Hunterbrook on September 18, 2025, revealed serious safety concerns, leading to a nearly 12% drop in stock price, equating to $8.99 per share [7].

Core Viewpoint - A class action lawsuit has been filed against Dexcom, Inc. for allegedly misleading investors about the safety and reliability of its continuous glucose monitoring systems, specifically the G6 and G7 models [1][2]. Allegations - The lawsuit claims that Dexcom made unauthorized material design changes to the G6 and G7 systems, which compromised their reliability and posed health risks to users [2]. - It is alleged that Dexcom overstated the enhancements and reliability of the G7 system while downplaying the severity of issues related to adulterated devices [2]. - The complaint suggests that these actions have exposed Dexcom to increased regulatory scrutiny and potential legal repercussions [2]. Impact of Hunterbrook Report - A report published by Hunterbrook on September 18, 2025, highlighted severe health risks associated with the G7 devices, including incidents of hospitalization and death linked to inaccurate glucose readings [3]. - Following the release of this report, Dexcom's stock price dropped by $8.99 per share, or 11.76%, closing at $67.45 on September 19, 2025 [3]. Class Action Participation - Investors who purchased Dexcom securities between July 26, 2024, and September 17, 2025, may be eligible to participate in the class action, with a deadline for lead plaintiff submissions set for December 29, 2025 [4].

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. and its senior executives for securities fraud following significant stock declines attributed to potential violations of federal securities laws [1][2]. Company Overview - DexCom manufactures continuous glucose monitoring (CGM) systems, including the Dexcom G6 and G7, which were marketed as highly accurate devices [3]. Allegations - The lawsuit alleges that DexCom made unauthorized design changes to the G6 and G7, compromising their accuracy and exposing customers to serious health risks while prioritizing cost reduction over safety [4]. Stock Performance - DexCom's stock experienced notable declines due to revelations about product quality issues: - On March 7, 2025, the stock fell by $7.12 per share (over 9%) following an FDA warning letter regarding manufacturing concerns [5]. - After the FDA's public disclosure on March 25, 2025, the stock dropped another $3.19 per share (over 4%) [6]. - A report published on September 18, 2025, indicated severe safety issues, leading to a nearly 12% decline of $8.99 per share over two trading days [7].

Core Insights - DexCom (DXCM) stock is currently trading within a support range of $55.31 to $61.13, where it has historically bounced back significantly, achieving an average peak return of 66.2% over the past decade [2]. Company Overview - DexCom specializes in continuous glucose monitoring systems, including the next-generation G7 CGM, which is available for use in the U.S. and internationally [4]. - The company has demonstrated a revenue growth rate of 9.3% over the last twelve months (LTM) and an average growth rate of 17.3% over the past three years [5]. - DexCom has a free cash flow margin of nearly 13.3% and an operating margin of 16.0% LTM [5]. Historical Performance - The stock has experienced significant declines during major market downturns, including a drop of nearly 87% during the Global Financial Crisis, 48% in the 2018 correction, and 58% during the inflation spike, as well as a 37% decline during the Covid pandemic [4][5]. - Despite these downturns, the stock has shown resilience and has recovered from past revenue shocks, with the lowest annual revenue growth in the last three years being 9.3% [5]. Valuation Metrics - DexCom stock is currently valued at a price-to-earnings (PE) multiple of 39.9 [5].

Core Viewpoint - A securities class action lawsuit has been filed against DexCom, Inc. for allegedly making false and misleading statements regarding its G6 and G7 continuous glucose monitoring systems, which may have posed health risks to users [1][2]. Allegations Against DexCom - The lawsuit claims that DexCom made unauthorized design changes to its G6 and G7 systems, which compromised their reliability and presented health risks to users [2]. - It is alleged that DexCom overstated the enhancements and reliability of the G7 device, downplaying the severity of issues related to the devices [2]. - The company is accused of exposing itself to increased regulatory scrutiny and potential legal, reputational, and financial harm due to these actions [2]. Lead Plaintiff Process - Investors in DexCom have until December 26, 2025, to seek appointment as a lead plaintiff in the class action, which involves directing the litigation on behalf of all class members [3]. - The lead plaintiff is typically the investor or group of investors with the largest financial interest in the case [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [4].

Core Viewpoint - A securities class action lawsuit has been filed against DexCom, Inc. for alleged misleading statements and undisclosed material changes to its glucose monitoring systems during the specified Class Period [1][2]. Allegations Against DexCom - The lawsuit claims that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [2]. - It is alleged that DexCom overstated the enhancements and reliability of the G7 device, downplaying the severity of issues related to the adulterated devices [2]. - The complaint suggests that these actions increased the risk of regulatory scrutiny and potential legal, reputational, and financial harm to DexCom [2]. Lead Plaintiff Process - Investors in DexCom have until December 26, 2025, to seek appointment as a lead plaintiff, representing the interests of the class in the litigation [3]. - The lead plaintiff is typically the investor or group of investors with the largest financial stake and who are representative of the class [3]. Contact Information - Kessler Topaz Meltzer & Check, LLP encourages affected DexCom investors to reach out for more information regarding the lawsuit [4].